Withdrawals due to adverse events · patients with axSpA (AS and nr‐axSpA)
COX‐2 NSAIDs showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
RR 2.14 [0.36, 12.56]
669 participants
Low
At least 50% reduction in pain · adults with strains, sprains, or muscle pull
2 findings from 1 review
Clinical success (eg 50% reduction in pain) Chronic conditions · adults with strains, sprains, or muscle pull
1 finding from 1 review
Serious adverse events · adults with strains, sprains, or muscle pull
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Pain intensity (0‐10cm visual analogue scale) · Adults with lateral elbow pain
1 finding from 1 review
Treatment success Fair, good or excellent effectiveness · Adults with lateral elbow pain
Topical NSAIDs may leads to higher treatment success Fair, good or excellent effectiveness compared with placebo (low certainty).
1 finding from 1 review
Function/disability · Adults with lateral elbow pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · Adults with lateral elbow pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Adults with lateral elbow pain
1 finding from 1 review
Adverse events · Adults with lateral elbow pain
Topical NSAIDs showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Pain (short term) WOMAC scale from 0 to 20 points (higher is worse pain). · patients with axSpA (AS and nr‐axSpA)
1 finding from 1 review
no estimate extracted
850 participants
High
Withdrawals due to adverse events · patients with axSpA (AS and nr‐axSpA)
Traditional NSAIDs showed no clear difference in withdrawals due to adverse events Due to adverse events compared with placebo (high certainty).
1 finding from 1 review
RR 0.75 [0.46, 1.21]
1165 participants
High
BASDAI Scale from 0 to 100 (higher is worse) · patients with axSpA (AS and nr‐axSpA)
1 finding from 1 review
no estimate extracted
190 participants
Moderate
BASFI Scale from 0 to 100 (higher is worse) · patients with axSpA (AS and nr‐axSpA)
1 finding from 1 review
no estimate extracted
356 participants
High
BASMI Scale from 0 to 10 (higher is worse) · patients with axSpA (AS and nr‐axSpA)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Radiographic progression · patients with axSpA (AS and nr‐axSpA)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of serious adverse events · patients with axSpA (AS and nr‐axSpA)
Traditional NSAIDs showed no clear difference in number of serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 1.69 [0.36, 7.97]
671 participants
Moderate
All‐cause mortality · cognitively healthy people in late life
Other NSAIDs showed no clear difference in mortality compared with placebo (moderate certainty).
1 finding from 1 review
Incidence of mild cognitive impairment · cognitively healthy people in late life
Other NSAIDs showed no clear difference in incidence of mild cognitive impairment compared with placebo (low certainty).
1 finding from 1 review
Activities of daily living · cognitively healthy people in late life
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found